News

6 October 2017

TBDO Sessions Lluís Armengol/Ruth Muñoz/Luis Ruiz/Leandro Vetcher

06/10/201710:00RAMÓN Y CAJALTBDO SessionsLluís Armengol/Ruth Muñoz/Luis Ruiz/Leandro VetcherCSO and CEO of qGenomics/CSO of Leukos Biotech/CEO at Spherium Biomed/Director of Harvard’s Blavatnik Biomedical AcceleratorRound Table discussion in the context of the 4th CRG BioBusiness School.Host: Cironi López, PabloAbstract:These four seasoned and new entrepreneurs in the biotech sector will share their motivations to become entrepreneurs, and experiences in doing so.

2 October 2017

TBDO Sessions Andrés G. Fernández

02/10/201709:30CHARLES DARWINTBDO SessionsAndrés G. FernándezFerrer Advanced Biotherapeutics"Biopharma industry: Decision process on project selection and investment prioritization"Host: Cironi López, PabloAbstract:As Director of Ferrer Advanced Biotherapeutics, the Biotech Research Division of Ferrer International, Andrés G. Fernández and his team work to actively identify and select high added-value biopharmaceutical projects that they help to transform into real products in a variety of therapeutic and diagnostic areas. Previous to his current position, Andrés held a number of executive and scientific responsibilities at Ferrer, Almirall and
Salvat laboratories, where he helped to successfully develop and launch an important...

6 September 2017

This one goes up to 11: researchers crack code for genetic ‘control dials’

CRG scientists develop a new technique to crack the underlying DNA code for the ‘control dials’ that determine levels of gene activity in bacteria.

1 August 2017

CaixaImpulse funds a project to develop a new cancer treatment based in aternative splicing

The AON project aims to develop new cancer treatment for lung adenocarcinoma based on antisense oligonucleotides acting selectively on key cancer related genes.

5 July 2017

An experimental technique analyses for the first time the functioning of human sperm before being inseminated into the egg

The work of the CRG and Eugin Group succeeds in observing the fertilisation capacity of the sperm cell before its insemination in the oocyte.

28 June 2017

The TBDO participated in the 2017 BIO International Convention in San Diego

The BIO International Convention (BIO) attracts over 15,000 biotechnology and pharma leaders who come together for one week of intensive networking and partnering meetings to discover new opportunities and promising partnerships. 

Read More

5 May 2017

PRBB-CRG Sessions Ricardo Macarrón

05/05/201712:00MARIE CURIEPRBB-CRG SessionsRicardo MacarrónEMTM, PhD, VP of Target and Pathway Validation, Target Sciences, GlaxoSmithKline- R&D, USA“Targets and leads: the complex world of drug discovery. Science in innovative companies: this is not the dark side”Host: Juan Valcárcel (CRG) and Pablo Cironi (CRG)

25 April 2017

TBDO Sessions Ryan Timothy Gill

25/04/201711:00R_473.10_AULATBDO SessionsRyan Timothy GillSlade Professor, Chemical and Biological Engineering. CSO, Muse Biotech"Impact in nontraditional manners: An academics journey through the startup world"Host: Cironi López, PabloAbstract:Abstract: Woud you rather change the world through a ground breaking scientific insight or through a new technology that changes the way people lived? A nature paper or a PCR machine? Creating 1000 jobs or educating 1000 students? These questions do not have to have mutually exclusive answers — in many centers of innovation faculty, leaders, and students are doing both, and doing them exceptionally well. In fact, in some cases it is expected that faculty will devote a certain amount of their to...

25 April 2017

New method to ensure reproducibility in computational experiments

It contributes to establishing good scientific practices and provides an important framework for those research projects where the analysis of large datasets are used to take decisions.

10 March 2017

The TBDO will participate in the Bio-Europe 2017 in Barcelona

BIO-Europe is Europe's largest partnering conference serving the global biotechnology industry. The conference annually attracts leading dealmakers from biotech, pharma and finance along with the most exciting emerging companies: a great opportunity for partnering, networking and promoting CRG technologies.

Read More

24 February 2017

Size matters... and structure too!

CRG Researchers developed Global Score, a method that allows, for the first time, to predict protein interactions with long non-coding RNAs.

3 February 2017

CaixaImpulse 2017 - New call for projects now open

Aimed at researchers in the fields of Healthcare and Life Sciences, interested in transferring research assets from the lab to society and the market.

Projects may be submitted from 1 February to 15 March 2017

Read More

27 January 2017

MicrobioMx wins the S2B Concept Challenge

MicrobioMx, a project led by CRG researchers Toni Gabaldon and Pedro González, wins the Science to Business (S2B) Concept Challenge 2016.

27 January 2017

New public-private initiative to develop a new therapy against aterosclerosis

The project - which has just received 700,000 euros in the Spanish 2016 Retos-Colaboracion call- is led by biotech Iproteos with the participation of the Biomedical Research Institute of Barcelona...

22 November 2016

Local company Made of Genes in ‘El cazador de cerebros’

Saturday November 5th, Made of Genes was in the TV program ‘El cazador de cerebros - ¿Querrías saber tu destino genético?’ broadcasted by TVE La 2.

View More

13 October 2016

CRG Proof of Concept: Commercialization Gap Fund (CGF)

Deadline : 01/11/2016 (Last days to apply!)

Please send your Full Proposal (max. 10 pages) under the following schemes:

  • MIDI - Up to 6 months and 35 kEUR
  • MAXI - Up to 12 months and 75 kEUR

Read More

7 October 2016

Science to Business (S2B) Concept Challenge

Deadline : 01/11/2016 (Last days to apply!)

Don't miss out on your opportunity to see your innovation go from conception to success. Send your application (max. 10 slides) addressing the following guidelines:

  • About You 1 slide
  • Technology 2–3 slides
  • Potential Applications 1-2 slides
  • Path to Market 1-2 slides
  • Risks 1 slide
  • Plan 1 slide

Read More

20 September 2016

Strengthening gene therapy for Huntington’s disease

A single injection of a new treatment has reduced the activity of the gene responsible for Huntington’s disease for several months in a trial in mice.

20 September 2016

"Dedos de Zinc, una posible solución a la enfermedad de Huntington" (CRG / Diario Médico)

"Dedos de Zinc, una posible solución a la enfermedad de Huntington" (CRG / Diario Médico)
20 September 2016

"Una inyección reduce la enfermedad de Huntington en ratones durante varios meses" (CRG / La Vanguardia.com)

"Una inyección reduce la enfermedad de Huntington en ratones durante varios meses" (CRG / La Vanguardia.com)
15 September 2016

"The long-sought cure to Huntington's disease" (CRG / Cordis)

"The long-sought cure to Huntington's disease" (CRG / Cordis)
8 September 2016

"The long-sought cure to Huntington's disease" (CRG / Research EU Results Magazine)

"The long-sought cure to Huntington's disease" (CRG / Research EU Results Magazine)
7 September 2016

Challenges and rewards of building a biotech

12/09/2016 09:45 CHARLES DARWIN Keynote talk in the in the context of the 3rd CRG BioBusiness School."Challenges and rewards of building a biotech"Marc Martinell, CEO and Founder at Minoryx Therapeutics
Find it out next Friday, September 12 at 09h45 by joining the session.

7 September 2016

Round-table: Why is this a good time to start your own company?

16/09/201610:00RAMON Y CAJAL
Find it out next Friday, September 16 at 10h00 by joining a round-table discussion with some of the most relevant members of our regional, as well as international ecosystem.

Expert panel

  • Alexandre Casta (Investment Manager at Caixa Capital Risk)
  • Oscar Flores (CEO and Founder of GenomCore)
  • Luis Ruiz (CEO at Spherium Biomed)
  • Leandro Vetcher (Associate Director of Business Development at Harvard OTD)

Chair

  • Pablo Cironi (Head TBDO-CRG)

The round table is open to all the PRBB community, and it takes place in the context of the 3rd CRG BioBusiness School to be held at CRG from 12-16 September 2016. For more details please check the WebPage http://tbdo.crg.eu/entrepreneurs/entrepreneurs-...

1 July 2016

CRG Proof of Concept: Commercialization Gap Fund (CGF)

Deadline (Short Submission): 01/09/2016

Please send your application (max. 2 pages) under the following schemes:

  • MIDI - Up to 6 months and 35 kEUR
  • MAXI - Up to 12 months and 75 kEUR

Read More

 

1 July 2016

3rd CRG BioBusiness School (Extended Deadline)

12th-16th September 2016

Based on the great success of the former editions, the 3rd CRG Bio-Business School shall:

  • Raise awareness about technology transfer among the participants through lectures and hands-on practical sessions;
  • Teach the challenges, opportunities and tools to successfully transfer basic knowledge "from the lab to the marketplace";
  • Identify projects with technology transfer/business potential that could otherwise remain undisclosed;
  • Match basic science in biomedicine, bioinformatics, etc. with business;
  • Have participants function as "signal amplifiers", able to spread the knowledge acquired amongst other colleagues, and apply it to new projects;
  • Stimulate a culture of innovation and entrepreneurship.

Registration is free and open online. Click here to register. Deadline (extended) 08 July2016

Read More

 

10 June 2016

The TBDO participated in the 2016 BIO International Convention in San Francisco

The BIO International Convention (BIO) attracts over 15,000 biotechnology and pharma leaders who come together for one week of intensive networking and partnering meetings to discover new opportunities and promising partnerships. 

Read More

7 June 2016

Clinical trial opens new avenues for pharmacological therapy in Down's syndrome

CRG and IMIM researchers show in a paper published in The Lancet Neurology that EGCG together with a cognitive stimulation protocol, might improve some cognitive domains in individuals...

2 June 2016

A new energy source within the cells

Scientists find evidence of a new energy source within cell nucleus. Their results shed light on how in exceptional situations cells can reprogram gene expression and point at a new player for...

1 June 2016

J&J Innovation and Janssen Pharmaceuticals launch the World Without Diseases QuickFire Challenge

Johnson & Johnson Innovation and Janssen Pharmaceuticals, Inc. are bringing together the consumer, medical device and pharmaceutical sectors to award a prize to the person or team who submits the best idea, technology, or solution that will address a critical health need for the world's population, with an emphasis on lung cancer and metabolism. 

Projects may be submitted from 1 April to 31 August 2016

Read More

26 May 2016

Pablo Cironi will moderate the “Open Innovation Models in Drug Discovery” panel at the 9TH Charité Entrepreneurship Summit 2016 in Berlin

The Charité Entrepreneurship Summit attracts annually 400+ international entrepreneurs, scientists, investors, and healthcare industry professionals. This international and cross-disciplinary event offers a unique platform for building new partnerships that will transform the life sciences and the healthcare industry. The 2016 Edition, “Rethink & Transform healthcare”, will feature highly relevant topics, such as the digitalization of health care, the role of open innovation in dramatically improving drug discovery, the prospects of genome editing and healthy aging, the influence of women in changing the healthcare ecosystem, the growing understanding of the impact of gender differences on research and the practice of medicine, and the importance of delivering value-based medicine.

Read More

22 April 2016

Cell therapy in regenerative medicine from an industrial focus

On initiative of the TBDO, Dr. Miguel Mulet will provide an overview of cell therapy in regenerative medicine from an industrial focus and how this field illustrates particularly well, the challenges and risks of the trip from science to product during PRBB-CRG Session of Friday April 29th 2016 from 12:00-13:00. In this overview, he will touch various aspects:

  • Cell therapy as a pharmaceutical product.
  • How Mechanism of Action has been a moving target in parallel with product development.
  • The intellectual property challenge of protecting inventions involving cells.
  • Adapting biologics regulation to cell therapy.
  • The long path of clinical development.
  • Moving from a laboratory craft to industrial manufacturing.
  • Commercialization and Market Access.

Miguel Mulet is Director of Strategy and New Projects in TiGenix, which is a leading European cell therapy company. His primary role at TiGenix is focused on aligning the functions that drive the cell therapy pipeline in Crohn’s Disease and Acute Myocardial Infarct. In addition, and besides business development activities to broaden the current pipeline, he is in charge of advancing the market readiness of the current platforms through implementation of new technologies and process improvement initiatives.

12 April 2016

New members and focus on the CRG Business Board

The CRG Business Board, an advisory body whose mission is to provide  guidance in business development, investment, entrepreneurial and innovation strategic activities, has been reshuffled.

5 April 2016

Rhythm of oscillations in cerebral cortex, key to understanding Down syndrome

Scientists at the CRG and IDIBAPS have made a first-ever identification of the alterations in the neuronal circuit that impact cerebral cortex physiology, and that could be the cause of cognitive...

1 April 2016

CaixaImpulse 2016 - New call for projects now open

Aimed at researchers in the fields of Healthcare and Life Sciences, interested in transferring research assets from the lab to society and the market.

Projects may be submitted from 1 April to 15 July 2016

Read More

1 April 2016

"Mind the Gap" 2016 - New call for projects now open

The Botín Foundation, with the "Mind the Gap" technology transfer investment programme, promotes the launch of business initiatives based on the results of scientific and technological research.

Projects may be submitted from 1 April to 28 April 2016

Contact the TBDO for more information and to request the application package.

10 March 2016

EiR Ion Arocena appointed new Managing Director of ASEBIO

Ion Arocena, one of our collaborators in the Entrepreneurs in Residence Programme, has been appointed new managing director of ASEBIO, the Spanish Bioindustry Association.

We wish him success in his new role!

Read More

11 February 2016

'From Science to Business' course, the first BIST joint initiative

The Barcelona Institute of Science and Technology (BIST) -an initiative of six top research centres in Catalonia including the CRG- and the...

5 February 2016

Pia Cosma, awarded the 'Ciutat de Barcelona' Prize 2015

The Barcelona City Council through the Institut de Cultura de Barcelona have announced the 2015 “Premi Ciutat...

5 February 2016

Pia Cosma, awarded the 'Ciutat de Barcelona' Prize 2015

The Barcelona City Council through the Institut de Cultura de Barcelona have announced the 2015 “Premi Ciutat...

4 February 2016

From Science to Business - BIST/ESADE Business School

Today’s global economy and business are facing a tremendous challenge: how to transform research, the money invested and the resources provided to laboratories and scientific parks into new innovations to create new products and services that can lead to the improvement of the life of individuals and society as a whole. One of the main barriers encountered is the “distance” between researchers and the business world. This distance is not usually physical, it is simply a lack of knowledge on both sides. Minimizing this distance would, without a doubt, improve the returns to society on the money invested in R&D. The participation of the scientist behind the invention and/or the researchers who decide to pursue a professional career in developing new businesses will significantly increase the odds of a successful new company.

This program is aimed at CRG researchers, senior researchers, postdoctoral fellows and last year doctoral students as well. It is also addressed to...

1 February 2016

Nereida Rodriguez joins the Entrepreneur-In-Residence Program

Nereida will collaborate with the TBDO department to enhance her proprietary technology, developed in conjunction with Xavier Gallego and Xavier Bosch: a next generation video tracking system able to automatically detect complex animal behaviors under any environmental condition.

Read More

1 February 2016

Xavier Bosch joins the Entrepreneur-In-Residence Program

Xavier will collaborate with the TBDO department to enhance his proprietary technology, developed in conjunction with Xavier Gallego and Nereida Rodriguez: a next generation video tracking system able to automatically detect complex animal behaviors under any environmental condition.

Read More

31 January 2016

TRANSFIERE 2016

On 10-11 February 2016, CRG will participate in Transfiere, the 5th European Forum for Science, Technology and Innovation, that will take place in the Palacio de Ferias y Congresos of Málaga.

Transfiere is the biggest professional and multisector forum of Spanish Innovation, in which participants can:

  • Establish B2B contacts 
  • Transfer scientific knowledge and lines of technological research 
  • Show their innovative products and services
  • Get to know the technological needs of Public Administration

Read More

14 January 2016

New tools for the diagnosis of multiple sclerosis in its early stages

Scientists at the CRG and VHIR develop a new method for early diagnosis of multiple sclerosis. The finding, based on measuring a combination of proteins, makes it possible to accurately predict...

14 January 2016

TBDO Sessions Malcolm Bain

14/01/201612:00473.10TBDO SessionsMalcolm BainID Law PartnersSoftware protection and licensing issues…with a focus towards commercializationHost: Cappadona, SalvatoreAbstract:Software protection and licensing issues …with a focus towards commercialization: Many outcomes produced by biomedical/genomic R+D today involve software and databases. This session focuses on the legal issues of ownership, protection and exploitation of software in this area, looking at both traditional “royalty bearing” licensing and free and open source licensing, and the provision of services “in the cloud” as opposed to on premise licensing. We also look at the use and protection of databases and their licensing. Bio: Malcolm Bain is an English solicitor and...

10 December 2015

Jordi Riulas joins the Entrepreneur-In-Residence Program

Jordi will collaborate with the TBDO team at CRG, analysing emerging business opportunities in the biotech market.

Read More

4 December 2015

Rory Johnson and members of the TBDO participated in the ‘Personalized Medicines & Biomarkers 2015’ conference in London

Rory Johnson, Ramon y Cajal fellow at the Computational Biology of RNA Processing laboratory, together with members of the TBDO team, participated in the “Personalized Medicines & Biomarkers 2015” conference, held in London UK on 2nd and 3rd December 2015. The participation to this event, organized within the frame of the Science to Business (S2B) Concept Challenge (2015 Edition) award, was a great opportunity to learn from, and network with, leaders from biotech and pharma in the field of biomarker discovery and development. We expect that this valuable experience will help Rory promoting his entrepreneurial project, focused on non-invasive RNA treatment-decision biomarkers for chronic lymphocytic leukemia.

Read More

3 December 2015

The TBDO participated in the BioFIT event in Strasbourg

BioFIT is the leading partnering event in Europe for open innovation, technology transfer and collaborative research in the field of Life Sciences: another great opportunity for partnering, networking and promoting CRG technologies.

Read More

30 October 2015

CRG Proof of Concept: Commercialization Gap Fund (CGF)

Deadline: 27/11/2015

Please send your Full Proposal (max. 10 pages) under the following schemes:

  • MIDI - Up to 6 months and 35 kEUR
  • MAXI - Up to 12 months and 75 kEUR

Read More

30 October 2015

The TBDO will participate in the Bio-Europe 2015 in Munich

BIO-Europe is Europe's largest partnering conference serving the global biotechnology industry. The conference annually attracts leading dealmakers from biotech, pharma and finance along with the most exciting emerging companies: a great opportunity for partnering, networking and promoting CRG technologies.

Read More

27 October 2015

Xavier Gallego joins the Entrepreneur-In-Residence Program

Xavier will collaborate with the TBDO team and CRG researchers to test a next generation video tracking systems that he has recently developed. The equipment is able to automatically detect complex rodent behaviors under any environmental condition. 
16 October 2015

Health & Bio Team Dating

On 3 December 2015, Banc SabadellBiocatCataloniaBio and the Bosch i Gimpera Foundation are holding Health & Bio Team Dating, an event where scientist and business professionals can talk about their projects and themselves with the aim of building a balanced team to lead successful start-up in the life sciences.

Read More

 

12 October 2015

Victor LLorente joins the Entrepreneur-In-Residence Program

Victor will collaborate with the TBDO team at CRG, looking for business opportunities based on innovative technologies in the software and medical sectors.

Read More

9 October 2015

TBDO Sessions Round-table discussion in the context of the 2nd CRG BioBusiness School.

09/10/201510:00CHARLES DARWINTBDO SessionsRound-table discussion in the context of the 2nd CRG BioBusiness School..What it takes to be an entrepreneurAbstract:“Start ups”, “spin-offs”, “innovation”, “entrepreneurship”… In advanced economies, technology-based company creation is perceived as an important motor of regional economic development. Many of such companies arise from publically funded research institutions, promoted in many cases by researchers like you. But… do you have what it takes to be a successful entrepreneur? Find it out next Friday, October 9th at 10h00 by joining a round-table discussion with some of the most relevant members of our regional, as well as international ecosystem.

The round table is open to all the PRBB community, and it...

8 October 2015

CRG Proof of Concept: Commercialization Gap Fund (CGF)

Deadline: 11/10/2015 (Approaching!)

Please send your application (max. 2 pages) under the following schemes:

  • MIDI - Up to 6 months and 35 kEUR
  • MAXI - Up to 12 months and 75 kEUR

Read More

 

24 September 2015

AstraZeneca embraces crowdsourcing in cancer R&D

UK pharma company jumps on the open access R&D bandwagon, offering access to data on over 50 of its drugs, with the aim of inspiring new combination therapies for cancer.

Read More

18 September 2015

New CRG Technology and Business Development Office

The CRG re-launches its technology transfer office, which emerges as the new Technology and Business Development Office.

2 September 2015

2nd CRG BioBusiness School

Based on the great success of the first edition, the 2nd CRG Bio-Business School shall:

  • Raise awareness about technology transfer among the participants through lectures and hands-on practical sessions;
  • Teach the challenges, opportunities and tools to successfully transfer basic knowledge "from the lab to the market";
  • Identify projects with technology transfer/business potential that could otherwise remain undisclosed;
  • Match basic science in biomedicine, bioinformatics, etc. with business;
  • Have participants function as "signal amplifiers", able to spread the knowledge acquired amongst other colleagues, and apply it to new projects;
  • Stimulate a culture of innovation and entrepreneurship.

The course is organized to train researchers in technology transfer and related areas (entrepreneurship, patents, and bio-business). This is in line with two of the main goals of the CRG: train the next...

8 July 2015

Neuroscience, technology, computer science and creativity come together to support people with disabilities

CRG, Starlab, UB and IMIM presented Brain Polyphony, an interdisciplinary project that aims to develop a system that translated brain waves into sound. The final goal is to improve communication...

10 June 2015

TBDO Sessions Richard J Law

10/06/201510:00R_473.10_AULATBDO SessionsRichard J LawEVOTEC"Structure based drug design guided by fragment screening & computational chemistry".Host: Tórtola Pérez, SilviaAbstract:Fragment based drug design has emerged as an effective alternative to high throughput screening for the identification of lead compounds in drug discovery in the past years. Screening of low molecular weight weak binders (“fragments”), and obtaining hits is a well understood process that can be achieved by many different assay techniques. Less well defined is how to proceed once a hit is obtained. Computational chemistry, and the application of...

12 May 2015

TBDO Sessions Dr. Antonio Gómez

12/05/201511:00MARIE CURIETBDO SessionsDr. Antonio GómezJohnson & Johnson"The search for new drugs at Johnson & Johnson: the mGluR2 project and the Innovation Centers"Abstract:Dr Antonio Gomez earned a PhD from the University of Salamanca in the field of Hemisynthesis of Natural Products in 1997. Joined Janssen-Cilag S.A. in Toledo in 1996, initially as a medicinal chemist. Then moved to Janssen Pharmaceutica in Belgium in 1999-2000 to work in the Department of Research Support. Back in Toledo he has held various positions as Project coordinator and scientific IP coordinator. Since 2012 he is in charge of external collaborations for the Toledo site. With the launch of the Innovation Center...